Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 21,326

Document Document Title
WO/2011/125836A1
Disclosed is a therapeutic agent or prophylactic agent that has analgesic effects on both nociceptive pain and neuropathic pain and is effective in the treatment of fibromyalgia. Specifically disclosed is a therapeutic agent or prophylac...  
WO/2011/121109A1
The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator .  
WO/2011/123456A1
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injec...  
WO/2011/117448A1
The invention relates to compounds for use in the treatment of diseases based on the expression of toxic transcripts. The invention relates to peptide molecules, specifically hexapeptides, for the prevention and/or treatment of diseases ...  
WO/2011/115183A1
Disclosed is a monocyclic pyrimidine derivative. To be more specific, the pyrimidine derivative is effective in the prophylaxis and/or treatment of disorders associated with signal transmission mediated by Toll-like receptors (TLR).  
WO/2011/115184A1
Disclosed is an inhibitor of in vivo proteolysis, which contains, as an active ingredient, a fatty acid compound that contains one acyl group having 6-12 carbon atoms. The inhibitor of in vivo proteolysis preferably contains, as an activ...  
WO/2011/111694A1
Disclosed is a monoclonal antibody against a biomarker capable of highly specific and effective use in the detection and diagnosis of various pathologies associated with various types of cancer nests and necrotic focuses. The monoclonal ...  
WO/2011/111698A1
Disclosed is a monoclonal antibody against a biomarker capable of highly specific and effective use in the detection and diagnosis of various pathologies associated with various types of cancer nests and necrotic focuses. The monoclonal ...  
WO/2011/111714A1
Disclosed are: a compound which has excellent metabolic stability and selectively binds to EP4 receptor; and a pharmaceutical product which contains the compound. Specifically disclosed is a compound represented by formula (1) (wherein R...  
WO/2011/108692A1
Disclosed is an agent for preventing muscular atrophy, which has an excellent preventive effect on muscular atrophy and comprises a whey protein hydrolysate. Specifically disclosed is an agent for preventing muscular atrophy, which compr...  
WO/2011/108009A2
The present invention relates to a process for the preparation of substantially pure fampridine compound of structural formula (I), (II), (III) comprising nitrifying pyridine-N-oxide hydrochloride with suitable nitrating agent; reducing ...  
WO/2011/109324A1
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...  
WO/2011/108487A1
Disclosed is a new usage, with the goal of preventing skeletal muscle atrophy, for a specific polyphenol that inhibits the expression of a gene that causes muscular atrophy. Also disclosed is a composition which inhibits muscular atrophy...  
WO/2011/108009A3
The present invention relates to a process for the preparation of substantially pure fampridine compound of structural formula (I), (II), (III) comprising nitrifying pyridine-N-oxide hydrochloride with suitable nitrating agent; reducing ...  
WO/2011/105572A1
A highly effective FAAH inhibitor, and especially a prophylactic or drug for severe pain, which can be administered orally, are needed. Provided is a pharmaceutical composition having as an active ingredient a novel heteroaryl derivative...  
WO/2011/101866A3
The present invention discloses a gastric retentive formulation (capsule or tablet) containing baclofen. Said formulation comprises an immediate and a sustained release part whereas the sustained release part is comprised in the core of ...  
WO/2011/102404A1
Disclosed are: a novel compound having an inhibitory activity on S1P lyase and capable of inducing the decrease in the number of lymphocytes or an isotope or pharmaceutically acceptable salt of the compound; and a pharmaceutical composit...  
WO/2011/096490A1
Disclosed is a prophylactic and/or therapeutic agent for rejection after transplant surgery and for diseases caused by immune system abnormalities, comprising a compound represented by formula (I) or a pharmacologically acceptable salt t...  
WO/2011/097500A2
The invention provides methods for preventing loss and augmenting regeneration of skeletal muscle by decreasing the activity of the TWEAK/Fn14 system.  
WO/2011/097456A3
The present invention provides methods and compositions for enhanced transduction of an adeno-associated virus (AAV) vector comprising a heterologous nucleic acid of interest wherein the AAV vector genome is oversized relative to a wild ...  
WO/2011/096484A1
A read through inducer for an immature termination codon formed by a nonsense mutation, which comprises a compound represented by structure formula (A); and a therapeutic agent for nonsense-mutation-type genetic diseases, which comprises...  
WO/2011/096377A1
Disclosed is a novel low molecular weight compound that has an immunosuppressive effect. Specifically disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, substituent...  
WO/2011/097500A3
The invention provides methods for preventing loss and augmenting regeneration of skeletal muscle by decreasing the activity of the TWEAK/Fn14 system.  
WO/2011/097456A2
The present invention provides methods and compositions for enhanced transduction of an adeno-associated virus (AAV) vector comprising a heterologous nucleic acid of interest wherein the AAV vector genome is oversized relative to a wild ...  
WO/2011/095893A1
A convenient and scalable synthesis of DGJNAc ID from D-glucuronolactone in an overall yield of 20% is provided. DGJNAc is the first highly potent and specific competitive inhibitor of GalNAcases. DGJNAc ID is also a competitive inhibito...  
WO/2011/090062A1
Disclosed are a piperazine compound represented by formula (1) and a salt thereof. (In the formula, X represents CH or a N atom, R1 represents a C1-6 alkyl group; R2 represents any of a C1-6 alkyl group optionally having a substituted ba...  
WO/2011/081173A1
A tetracyclic compound represented by formula (I) (wherein Q represents -O- or the like; X represents CH or the like; R1 represents a lower alkyl group or the like; R2 and R3 independently represent a hydrogen atom or the like; and R4 an...  
WO/2011/077252A2
The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of metaxalone. Disclosed herein are several new cocrystals of metaxalone, including: a 1:1 metaxalore adipic acid cocrystal, a 1:0.5 metaxal...  
WO/2011/077252A3
The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of metaxalone. Disclosed herein are several new cocrystals of metaxalone, including: a 1:1 metaxalore adipic acid cocrystal, a 1:0.5 metaxal...  
WO/2011/078221A1
By making a search for many various compounds having inhibitory activity against IL-12/IL-23 production, provided are medicinal compositions that contain the compounds and therapeutic or prophylactic agents that contain the compounds and...  
WO/2011/076811A1
The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also rela...  
WO/2011/078360A1
Disclosed is a compound represented by formula (I) or a salt thereof, which has GPR52 agonist activity and is useful as a prophylactic or therapeutic agent for schizophrenia and the like. (In the formula, ring Cy1 represents a five-membe...  
WO/2011/071136A1
A therapeutic agent for fibromyalgia, comprising a 5-HT2C receptor agonist as an active ingredient.  
WO/2011/070541A1
Compounds of the formula (I) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C...  
WO/2011/070539A1
Compounds of Formula (II) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C...  
WO/2011/066656A1
Pharmaceutical compositions and methods for improving functional capacity of tissues and organs in both healthy and pathologic disease states for: reducing unwanted cosmetic effects of aging on the skin to reduce wrinkles, to increase co...  
WO/2011/068208A1
Disclosed is a novel treatment strategy for spinal and bulbar muscular atrophy (SBMA). Specifically disclosed is a therapeutic agent for spinal and bulbar muscular atrophy, which comprises triptan or a pharmacologically acceptable salt t...  
WO/2011/068171A1
Provided are compounds having prophylactic and/or therapeutic effect on chronic rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn diseases and ulcerative colitis, autoimmune diseases typified by psoriasi...  
WO/2011/065791A2
The present invention provides a composition comprising Astragali Radix extract as an active ingredient. The composition can increase body energy consumption and muscle metabolism. The present invention also relates to pharmaceutical and...  
WO/2011/065791A3
The present invention provides a composition comprising Astragali Radix extract as an active ingredient. The composition can increase body energy consumption and muscle metabolism. The present invention also relates to pharmaceutical and...  
WO/2011/064552A1
A construct suitable for delivery of a biologically active compound into cells, comprising: (d) a positively charged peptide; (e) a targeting-delivery peptide; and (f) the biologically active compound; wherein the positively charged pept...  
WO/2011/062253A1
Disclosed is a prophylactic and/or therapeutic agent for diseases associated with autoimmunity, immune deficiency diseases or neurodegenerative diseases, said prophylactic and/or therapeutic agent containing a novel fused pyrimidine deri...  
WO/2011/060488A1
The invention relates to a recombinant microorganism comprising a transgene encoding angiogenin and optionally follistatin, a food product, beverage product or animal feed produced from or comprising said microorganism and uses thereof.  
WO/2011/058766A1
The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is -O-, -S-, -SO- or –SO2-, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have block...  
WO/2011/059021A1
Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A represents a group that is represented by formula (A-1); R1a and R1b may be the same or different and each independentl...  
WO/2011/057350A1
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.  
WO/2011/054659A1
The present invention relates to methods for restoring the function of a mutated dysferlin comprising the step of preventing splicing of one or more exons which encode amino acid sequences that cause said dysferlin dysfunction. Particula...  
WO/2011/056549A1
Dietary supplement compositions include an adaptogenic agent, an anti- inflammation agent, and an anti-oxidant. Methods for using dietary supplement compositions include (i) inhibiting, decreasing, and/or preventing delayed onset of musc...  
WO/2011/055944A2
The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.  
WO/2011/055944A3
The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.  

Matches 701 - 750 out of 21,326